One Kendall Square
Building 1400W, Suite 14303
Cambridge, MA 02139 USA
1/3 High-Tech Village, Givat Ram, Jerusalem, Israel
PO Box 39264, Jerusalem 9139102, Israel
BioCanCell is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer. (Read More)
Dr. Haluska has served as BioCanCell’s CEO since October 2016. He most recently served as Chief Medical Officer and Senior Vice President of Clinical R&D at ARIAD Pharmaceuticals, Inc., where he held overall responsibility for clinical development strategy. At ARIAD he led the clinical development and approval of ponatinib (marketed as Iclusig) in the US, EU and other territories, as well as the development of brigatinib, approved in the US by the FDA.
Dr. Haluska graduated from Harvard College and the University of Pennsylvania School of Medicine, undertook medical training at Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI), and a fellowship at the Massachusetts Institute of Technology Center for Cancer Research. He became assistant professor of medicine at Harvard Medical School, and leader of the melanoma research programs at the MGH Cancer Center and the DFCI through the Dana-Farber Harvard Cancer Center. Subsequently he was deputy director of the Tufts New England Medical Center Cancer Center. He has also served as a flight surgeon in the U.S. Air Force, and continues to serve in the Massachusetts Air National Guard with the rank of Colonel.